Vol 1, No 2 (June 30, 2012): Translational Lung Cancer Research

Maintenance Therapy1

Gefitinib NSCLC maintenance therapy
Martin H. Cohen
Translational Lung Cancer Research  
2012;
1
(2)
:94-95
.
Biomarkers in the selection of maintenance therapy in non-small cell lung cancer
Nichole T. Tanner, Carol A. Sherman, Gerard A. Silvestri
Translational Lung Cancer Research  
2012;
1
(2)
:96-98
.
A strong step forward in maintenance therapy for non-small cell lung cancer treatment
Edgardo S. Santos, Tarek Mekhail
Translational Lung Cancer Research  
2012;
1
(2)
:99-101
.
INFORM; C-TONG 0805: A multicenter, double blind randomizedphase III trial of maintenance gefitinib compared to placebo inadvanced non-small cell lung cancer
Thomas E. Stinchcombe
Translational Lung Cancer Research  
2012;
1
(2)
:102-104
.
Maintenance therapy in non-small cell lung cancer
Gerald Schmid-Bindert
Translational Lung Cancer Research  
2012;
1
(2)
:105-110
.

Review Articles

From tissue to molecular phenotyping: Pre-analytical requirements
Thomas R. Muley, Felix JF. Herth, Philipp A. Schnabel, Hendrik Dienemann, Michael Meister
Translational Lung Cancer Research  
2012;
1
(2)
:111-121
.
Targeting angiogenesis in lung cancer-Pitfalls in drug development
Wolfgang Hilbe, Christian Manegold, Andreas Pircher
Translational Lung Cancer Research  
2012;
1
(2)
:122-128
.

Original Article

Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis
Hui Gao, Xin Ding, Dong Wei, Peng Cheng, Xiaomei Su, Huanyi Liu, Fahad Aziz, Daoyuan Wang, Tao Zhang
Translational Lung Cancer Research  
2012;
1
(2)
:129-144
.

Perspectives

EGFR IHC score for selection of cetuximab treatment: Ready for clinical practice?
Martin Früh, Miklos Pless
Translational Lung Cancer Research  
2012;
1
(2)
:145-146
.
TKIs in NSCLC: The down of a new era?
Adrianni Charpidou, Kostas N Syrigos
Translational Lung Cancer Research  
2012;
1
(2)
:147-148
.
Treating acquired resistance to EGFR-tyrosine kinase inhibitors: Still a work in progress
Nathan A. Pennell
Translational Lung Cancer Research  
2012;
1
(2)
:149-151
.
Is there a third line option after chemotherapy and TKI failure in advanced non-small cell lung cancer?
Jacques De Grève, Lore Decoster, David van Brummelen, Caroline Geers, Denis Schallier
Translational Lung Cancer Research  
2012;
1
(2)
:152-154
.

Editorials

TRAIL apoptotic pathway-targeted therapies for NSCLC
Anita C. Bellail, Chunhai Hao
Translational Lung Cancer Research  
2012;
1
(2)
:155-157
.
Dulanermin in cancer therapy: Still much to do
Cristina Quintavalle, Gerolama Condorelli
Translational Lung Cancer Research  
2012;
1
(2)
:158-159
.
EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMation
Lorenza Landi, Federico Cappuzzo
Translational Lung Cancer Research  
2012;
1
(2)
:160-162
.

Disclosure:

1.  The series “Maintenance Therapy” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding.